RET and cancer: The ARROW trial integrated a phase I dose escalation (from 30 to 600 mg once daily) to establish the maximum tolerated dose of pralsetinib, and phase II expansion cohorts (400 mg/daily) enrolling patients with RET-mutant cancers (ClinicalTrials.gov, Identifier NCT03037385) (60).